<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:voc="urn:hl7-org:v3/voc" xmlns="urn:hl7-org:v3" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="f1a5d2f7-61eb-4be0-b082-bf382355672a"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use METFORMIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS safely and effectively. See full prescribing information for METFORMIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS.
         <br/>METFORMIN HYDROCHLORIDE extended-release tablets, for oral use
         <br/>Initial U.S. Approval: 1995 
   </title>
   <effectiveTime value="20250425"/>
   <setId root="1dc48913-f0b3-71fd-43e8-81d195af2414"/>
   <versionNumber value="4"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="845263701" root="1.3.6.1.4.1.519.1"/>
            <name>Apotex Corp.</name>
            <assignedEntity>
               <assignedOrganization>
                  <id extension="209429182" root="1.3.6.1.4.1.519.1"/>
                  <name>Apotex Inc.</name>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="5166bc1b-5ad7-97a2-1c18-8cc76eb5b953"/>
               <code code="48780-1" displayName="SPL PRODUCT DATA ELEMENTS SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <effectiveTime value="20250425"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="60505-4701" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Metformin Hydrochloride Extended-Release</name>
                        <formCode code="C42998" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Metformin Hydrochloride Extended-Release </name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="1000"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="786Z46389E" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>METFORMIN HYDROCHLORIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="9100L32L2N" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>Metformin</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="F68VH75CJC" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CARBOMER HOMOPOLYMER TYPE A (ALLYL PENTAERYTHRITOL CROSSLINKED)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="L11K75P92J" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ANHYDROUS DIBASIC CALCIUM PHOSPHATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="4W5IH7FLNY" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>DIBUTYL SEBACATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="B1QE5P712K" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE 2208 (100 MPA.S)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3DYK7UYZ62" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ETHYLCELLULOSE (10 MPA.S)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="HHT01ZNK31" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CARBOMER HOMOPOLYMER TYPE B (ALLYL PENTAERYTHRITOL CROSSLINKED)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="R75537T0T4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE 2910 (5 MPA.S)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="90"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code codeSystem="2.16.840.1.113883.6.69" code="60505-4701-9"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="completed"/>
                                 <effectiveTime>
                                    <low value="20230814"/>
                                    <high value="20260131"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="100"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code codeSystem="2.16.840.1.113883.6.69" code="60505-4701-1"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="completed"/>
                                 <effectiveTime>
                                    <low value="20230814"/>
                                    <high value="20230814"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="500"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code codeSystem="2.16.840.1.113883.6.69" code="60505-4701-5"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="completed"/>
                                 <effectiveTime>
                                    <low value="20230814"/>
                                    <high value="20230814"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="completed"/>
                           <effectiveTime>
                              <low value="20230814"/>
                              <high value="20260131"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA213356" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" displayName="WHITE" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48345" displayName="OVAL" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CE">
                              <originalText>oval biconvex</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">M;A</value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="19" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="60505-4700" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Metformin Hydrochloride Extended-Release</name>
                        <formCode code="C42998" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Metformin Hydrochloride Extended-Release </name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="500"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="786Z46389E" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>METFORMIN HYDROCHLORIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="9100L32L2N" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>Metformin</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="F68VH75CJC" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CARBOMER HOMOPOLYMER TYPE A (ALLYL PENTAERYTHRITOL CROSSLINKED)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="L11K75P92J" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ANHYDROUS DIBASIC CALCIUM PHOSPHATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="4W5IH7FLNY" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>DIBUTYL SEBACATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="B1QE5P712K" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE 2208 (100 MPA.S)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3DYK7UYZ62" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ETHYLCELLULOSE (10 MPA.S)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="HHT01ZNK31" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CARBOMER HOMOPOLYMER TYPE B (ALLYL PENTAERYTHRITOL CROSSLINKED)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="R75537T0T4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE 2910 (5 MPA.S)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="100"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code codeSystem="2.16.840.1.113883.6.69" code="60505-4700-1"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="completed"/>
                                 <effectiveTime>
                                    <low value="20230814"/>
                                    <high value="20260131"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="500"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code codeSystem="2.16.840.1.113883.6.69" code="60505-4700-5"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="completed"/>
                                 <effectiveTime>
                                    <low value="20230814"/>
                                    <high value="20230814"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="completed"/>
                           <effectiveTime>
                              <low value="20230814"/>
                              <high value="20260131"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA213356" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" displayName="WHITE" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48345" displayName="OVAL" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CE">
                              <originalText>oval biconvex</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="15" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">M5</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <component>
                  <section>
                     <id root="532309c3-3728-a3fe-2c51-578ed9f90ebf"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <effectiveTime value="20190320"/>
                     <component>
                        <observationMedia ID="MM346065517862">
                           <text>Structure.jpg</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="Structure.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="MM281178756381">
                           <text>LBL1000MG90S.jpg</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="LBL1000MG90S.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="MM309767141769">
                           <text>LBL500MG100S.jpg</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="LBL500MG100S.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="BOXED_WARNING">
               <id root="040dac02-a7bb-70c6-6a6e-048fa591477f"/>
               <code code="34066-1" displayName="BOXED WARNING SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>WARNING: LACTIC ACIDOSIS</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. The onset of metformin-associated lactic acidosis is often subtle, accompanied only by nonspecific symptoms such as malaise, myalgias, respiratory distress, somnolence, and abdominal pain. Metformin-associated lactic acidosis was characterized by elevated blood lactate levels (&gt; 5 mmol/Liter), anion gap acidosis (without evidence of ketonuria or ketonemia), an increased lactate/pyruvate ratio, and metformin plasma levels generally &gt; 5 mcg/mL [see Warnings and Precautions (<linkHtml href="#_ae6d682f-d855-4b68-f67a-cfba27a7d629">5.1</linkHtml>)].</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Risk factors for metformin-associated lactic acidosis include renal impairment, concomitant use of certain drugs (e.g., carbonic anhydrase inhibitors such as topiramate), age 65 years old or greater, having a radiological study with contrast, surgery and other procedures, hypoxic states (e.g., acute congestive heart failure), excessive alcohol intake, and hepatic impairment.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Steps to reduce the risk of and manage metformin-associated lactic acidosis in these high risk groups are provided in the full prescribing information [see Dosage and Administration (<linkHtml href="#_b5699d37-b2b7-e4fe-d783-b8faa8313f77">2.2</linkHtml>), Contraindications (<linkHtml href="#CONTRAINDICATIONS">4</linkHtml>), Warnings and Precautions (<linkHtml href="#_ae6d682f-d855-4b68-f67a-cfba27a7d629">5.1</linkHtml>), and Drug Interactions (<linkHtml href="#DRUG_INTERACTIONS">7</linkHtml>)].</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">If metformin-associated lactic acidosis is suspected, immediately discontinue metformin hydrochloride extended-release tablets and institute general supportive measures in a hospital setting. Prompt hemodialysis is recommended [see Warnings and Precautions (<linkHtml href="bold">5.1</linkHtml>)].</content>
                  </paragraph>
               </text>
               <effectiveTime value="20191010"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>
                           <content styleCode="bold">WARNING: LACTIC ACIDOSIS</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold italics">See full prescribing information for complete boxed warning.</content>
                        </paragraph>
                        <list>
                           <item>
                              <content styleCode="bold">Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. Symptoms included malaise, myalgias, respiratory distress, somnolence, and abdominal pain. Laboratory abnormalities included elevated blood lactate levels, anion gap acidosis, increased lactate/pyruvate ratio; and metformin plasma levels generally &gt; 5 mcg/mL. (<linkHtml href="#_ae6d682f-d855-4b68-f67a-cfba27a7d629">5.1</linkHtml>)</content>
                           </item>
                           <item>
                              <content styleCode="bold">Risk factors include renal impairment, concomitant use of certain drugs, age ≥ 65 years old, radiological studies with contrast, surgery and other procedures, hypoxic states, excessive alcohol intake, and hepatic impairment. Steps to reduce the risk of and manage metformin-associated lactic acidosis in these high-risk groups are provided in the Full Prescribing Information. (<linkHtml href="#_ae6d682f-d855-4b68-f67a-cfba27a7d629">5.1</linkHtml>)</content>
                           </item>
                           <item>
                              <content styleCode="bold">If lactic acidosis is suspected, discontinue metformin hydrochloride extended-release tablets and institute general supportive measures in a hospital setting. Prompt hemodialysis is recommended. (<linkHtml href="#_ae6d682f-d855-4b68-f67a-cfba27a7d629">5.1</linkHtml>)</content>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="INDICATIONS_AND_USAGE">
               <id root="0ad1f0b6-cfbf-b8b4-5561-7cebdabd3633"/>
               <code code="34067-9" displayName="INDICATIONS &amp; USAGE SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>Metformin hydrochloride extended-release tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.</paragraph>
               </text>
               <effectiveTime value="20191010"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Metformin hydrochloride extended-release tablets are a biguanide indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. <linkHtml href="#INDICATIONS_AND_USAGE">(1)</linkHtml>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="DOSAGE_AND_ADMINISTRATION">
               <id root="c9a038f2-7482-d00c-94e9-1443e61cd05e"/>
               <code code="34068-7" displayName="DOSAGE &amp; ADMINISTRATION SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <text>
                  <paragraph/>
               </text>
               <effectiveTime value="20191010"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph/>
                        <list>
                           <item>Starting dose: 500 mg orally once daily with the evening meal <linkHtml href="#_7311ae99-bdca-155d-76d8-511112a8ca42">(2.1)</linkHtml>
                           </item>
                           <item>Increase the dose in increments of 500 mg every 1 to 2 weeks, up to a maximum of 2,000 mg once daily with the evening meal. <linkHtml href="#_7311ae99-bdca-155d-76d8-511112a8ca42">(2.1)</linkHtml>
                           </item>
                           <item>Patients receiving metformin hydrochloride (HCl) tablets may be switched to metformin hydrochloride extended-release tablets once daily at the same total daily dose, up to 2,000 mg once daily. <linkHtml href="#_7311ae99-bdca-155d-76d8-511112a8ca42">(2.1)</linkHtml>
                           </item>
                           <item>Swallow metformin hydrochloride extended-release tablets whole and never crush, cut or chew. <linkHtml href="#_7311ae99-bdca-155d-76d8-511112a8ca42">(2.1)</linkHtml> </item>
                        </list>
                        <paragraph>
                           <content styleCode="underline">Renal Impairment:</content>
                        </paragraph>
                        <paragraph/>
                        <list>
                           <item>Prior to initiation, assess renal function with estimated glomerular filtration rate (eGFR). <linkHtml href="#_b5699d37-b2b7-e4fe-d783-b8faa8313f77">(2.2)</linkHtml>
                              <list>
                                 <item>Do not use in patients with eGFR below 30 mL/minute/1.73 m<sup>2</sup>.</item>
                                 <item>Initiation is not recommended in patients with eGFR between 30 to 45 mL/minute/1.73 m<sup>2</sup>.</item>
                                 <item>Assess risk/benefit of continuing metformin hydrochloride extended-release tablets if eGFR falls below 45 mL/minute/1.73 m<sup>2</sup>.</item>
                                 <item>Discontinue if eGFR falls below 30 mL/minute/1.73 m<sup>2</sup>.</item>
                              </list>
                           </item>
                        </list>
                        <paragraph>
                           <content styleCode="underline">Discontinuation for Iodinated Contrast Imaging Procedures:</content>
                        </paragraph>
                        <paragraph/>
                        <list>
                           <item>Metformin hydrochloride extended-release tablets may need to be discontinued at time of, or prior to, iodinated contrast imaging procedures. <linkHtml href="#_8338aad5-147c-c685-5166-3db1733a1b30">(2.3)</linkHtml>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="_7311ae99-bdca-155d-76d8-511112a8ca42">
                     <id root="d86fbbf7-7b2d-e4bb-4905-6db4c93cc541"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>2.1 Adult Dosage and Administration</title>
                     <text>
                        <paragraph/>
                        <list>
                           <item>The recommended starting dose of metformin hydrochloride extended-release tablets is 500 mg orally once daily with the evening meal.</item>
                           <item>Increase the dose in increments of 500 mg every 1 to 2 weeks on the basis of glycemic control and tolerability, up to a maximum of 2,000 mg once daily with the evening meal.</item>
                           <item>Patients receiving metformin hydrochloride (HCl) may be switched to metformin hydrochloride extended-release tablets once daily at the same total daily dose, up to 2,000 mg once daily.</item>
                           <item>Swallow metformin hydrochloride extended-release tablets whole and never crush, cut or chew.</item>
                           <item>If a dose of metformin hydrochloride extended-release tablets is missed, instruct patients not to take two doses the same day and to resume their usual dose of metformin hydrochloride extended-release tablets with the next schedule dose.</item>
                        </list>
                     </text>
                     <effectiveTime value="20190320"/>
                  </section>
               </component>
               <component>
                  <section ID="_b5699d37-b2b7-e4fe-d783-b8faa8313f77">
                     <id root="d09893e5-cc35-770c-4997-03a741d29807"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>2.2 Recommendations for Use in Renal Impairment</title>
                     <text>
                        <paragraph/>
                        <list>
                           <item>Assess renal function prior to initiation of metformin hydrochloride extended-release tablets and periodically thereafter.</item>
                           <item>Metformin hydrochloride extended-release tablets are contraindicated in patients with an estimated glomerular filtration rate (eGFR) below 30 mL/minute/1.73 m<sup>2</sup>.</item>
                           <item>Initiation of metformin hydrochloride extended-release tablets in patients with an eGFR between 30 to 45 mL/minute/1.73 m<sup>2</sup> is not recommended.</item>
                           <item>In patients taking metformin hydrochloride extended-release tablets whose eGFR later falls below 45 mL/minute/1.73 m<sup>2</sup>, assess the benefit risk of continuing therapy.</item>
                           <item>Discontinue metformin hydrochloride extended-release tablets if the patient’s eGFR later falls below 30 mL/minute/1.73 m<sup>2</sup>
                              <content styleCode="italics"> [see Contraindications (<linkHtml href="#CONTRAINDICATIONS">4</linkHtml>) and Warnings and Precautions (<linkHtml href="#_ae6d682f-d855-4b68-f67a-cfba27a7d629">5.1</linkHtml>)].</content>
                           </item>
                        </list>
                     </text>
                     <effectiveTime value="20190320"/>
                  </section>
               </component>
               <component>
                  <section ID="_8338aad5-147c-c685-5166-3db1733a1b30">
                     <id root="fc107199-4051-c290-5521-093d6bf35319"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>2.3 Discontinuation for Iodinated Contrast Imaging Procedures</title>
                     <text>
                        <paragraph>Discontinue metformin hydrochloride extended-release tablets at the time of, or prior to, an iodinated contrast imaging procedure in patients with an eGFR between 30 and 60 mL/minute/1.73 m<sup>2</sup>; in patients with a history of liver disease, alcoholism or heart failure; or in patients who will be administered intra-arterial iodinated contrast. Re-evaluate eGFR 48 hours after the imaging procedure; restart metformin hydrochloride extended-release tablets if renal function is stable<content styleCode="italics"> [see Warnings and Precautions (<linkHtml href="#_ae6d682f-d855-4b68-f67a-cfba27a7d629">5.1</linkHtml>)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20190320"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="DOSAGE_FORMS_AND_STRENGTHS">
               <id root="cd95aaf3-a1b7-495a-c955-d7c99f5354c3"/>
               <code code="43678-2" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>Metformin hydrochloride extended-release tablets, USP are available as:</paragraph>
                  <list>
                     <item>
                        <content styleCode="italics">Extended-release tablets:</content> 500 mg white to off-white, oval, beveled edge, biconvex film-coated tablet. Engraved “M5” on one side, plain on the other side.</item>
                  </list>
                  <list>
                     <item>
                        <content styleCode="italics">Extended-release tablets:</content> 1,000 mg white to off-white, oval, beveled edge, biconvex film-coated tablet. Engraved “M” on one side, “A” on the other side.</item>
                  </list>
               </text>
               <effectiveTime value="20200521"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Metformin hydrochloride extended-release tablets: 500 mg and 1,000 mg <linkHtml href="#DOSAGE_FORMS_AND_STRENGTHS">(3)</linkHtml>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="CONTRAINDICATIONS">
               <id root="900c30c4-7f51-f6f7-b6d3-c6e3db2d2c77"/>
               <code code="34070-3" displayName="CONTRAINDICATIONS SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>Metformin hydrochloride extended-release tablets are contraindicated in patients with:</paragraph>
                  <list>
                     <item>Severe renal impairment (eGFR below 30 mL/minute/1.73 m<sup>2</sup>) <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#_ae6d682f-d855-4b68-f67a-cfba27a7d629">5.1</linkHtml>)].</content>
                     </item>
                     <item>Known hypersensitivity to metformin.</item>
                     <item>Acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma.</item>
                  </list>
               </text>
               <effectiveTime value="20191010"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list>
                           <item>Severe renal impairment: (eGFR below 30 mL/minute/1.73 m<sup>2</sup>) <linkHtml href="#CONTRAINDICATIONS">(4</linkHtml>, <linkHtml href="#_ae6d682f-d855-4b68-f67a-cfba27a7d629">5.1</linkHtml>)</item>
                           <item>Known hypersensitivity to metformin <linkHtml href="#CONTRAINDICATIONS">(4)</linkHtml>
                           </item>
                           <item>Acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma <linkHtml href="#CONTRAINDICATIONS">(4)</linkHtml>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="WARNINGS_AND_PRECAUTIONS">
               <id root="c26a2f46-e781-5723-b91a-c3e249ad00e6"/>
               <code code="43685-7" displayName="WARNINGS AND PRECAUTIONS SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <text/>
               <effectiveTime value="20190320"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph/>
                        <list>
                           <item>
                              <content styleCode="italics">Lactic Acidosis: </content>See boxed warning. <linkHtml href="#_ae6d682f-d855-4b68-f67a-cfba27a7d629">(5.1)</linkHtml>
                           </item>
                           <item>
                              <content styleCode="italics">Vitamin B<sub>12</sub> Deficiency:</content> Metformin may lower vitamin B<sub>12</sub> levels. Monitor hematological parameters annually and vitamin B<sub>12</sub> at 2 to 3 year intervals and manage any abnormalities. <linkHtml href="#_c866af6b-c1c8-f372-93d1-c4da5a4bae52">(5.2)</linkHtml>
                           </item>
                           <item>
                              <content styleCode="italics">Hypoglycemia with Concomitant Use with Insulin and Insulin Secretagogues: </content>Increased risk of hypoglycemia when used in combination with insulin and/or an insulin secretagogue. Lower dose of insulin or insulin secretagogue may be required. <linkHtml href="#_0cbe5ec8-7ea8-1dd6-b9c4-a308ea0009d1">(5.3)</linkHtml>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="_ae6d682f-d855-4b68-f67a-cfba27a7d629">
                     <id root="ecb906da-9044-9c71-e931-f088c1ac0cea"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>5.1 Lactic Acidosis</title>
                     <text>
                        <paragraph>There have been postmarketing cases of metformin-associated lactic acidosis, including fatal cases. These cases had a subtle onset and were accompanied by nonspecific symptoms such as malaise, myalgias, abdominal pain, respiratory distress, or increased somnolence; however, hypothermia, hypotension and resistant bradyarrhythmias have occurred with severe acidosis. Metformin-associated lactic acidosis was characterized by elevated blood lactate concentrations (&gt;5 mmol/Liter), anion gap acidosis (without evidence of ketonuria or ketonemia), and an increased lactate/pyruvate ratio; metformin plasma levels were generally &gt; 5 mcg/mL. Metformin decreases liver uptake of lactate increasing lactate blood levels which may increase the risk of lactic acidosis, especially in patients at risk.</paragraph>
                        <paragraph>If metformin-associated lactic acidosis is suspected, general supportive measures should be instituted promptly in a hospital setting, along with immediate discontinuation of metformin hydrochloride extended-release tablets. In metformin hydrochloride extended-release tablets treated patients with a diagnosis or strong suspicion of lactic acidosis, prompt hemodialysis is recommended to correct the acidosis and remove accumulated metformin (metformin HCl is dialyzable, with a clearance of up to 170 mL/minute under good hemodynamic conditions). Hemodialysis has often resulted in reversal of symptoms and recovery.</paragraph>
                        <paragraph>Educate patients and their families about the symptoms of lactic acidosis and if these symptoms occur instruct them to discontinue metformin hydrochloride extended-release tablets and report these symptoms to their healthcare provider.</paragraph>
                        <paragraph>For each of the known and possible risk factors for metformin-associated lactic acidosis, recommendations to reduce the risk of and manage metformin-associated lactic acidosis are provided below:</paragraph>
                        <paragraph/>
                        <list>
                           <item>
                              <content styleCode="italics">Renal Impairment:</content> The postmarketing metformin-associated lactic acidosis cases primarily occurred in patients with significant renal impairment.<br/>
                              <paragraph>The risk of metformin accumulation and metformin-associated lactic acidosis increases with the severity of renal impairment because metformin is substantially excreted by the kidney. Clinical recommendations based upon the patient’s renal function include<content styleCode="italics"> [see Dosage and Administration (<linkHtml href="#_b5699d37-b2b7-e4fe-d783-b8faa8313f77">2.2</linkHtml>) and Clinical Pharmacology (<linkHtml href="#PHARMACOKINETICS">12.3</linkHtml>)]:</content>
                              </paragraph>
                           </item>
                        </list>
                        <list>
                           <item>Before initiating metformin hydrochloride extended-release tablets, obtain an estimated glomerular filtration rate (eGFR).</item>
                           <item>Metformin hydrochloride extended-release tablets are contraindicated in patients with an eGFR less than 30 mL/minute/1.73 m<sup>2</sup> <content styleCode="italics">[see Contraindications (<linkHtml href="#CONTRAINDICATIONS">4</linkHtml>)]</content>.</item>
                           <item>Initiation of metformin hydrochloride extended-release tablets is not recommended in patients with eGFR between 30 to 45 mL/minute/1.73 m<sup>2</sup>.  </item>
                           <item> Obtain an eGFR at least annually in all patients taking metformin hydrochloride extended-release tablets. In patients at increased risk for the development of renal impairment (e.g., the elderly), renal function should be assessed more frequently.  </item>
                           <item> In patients taking metformin hydrochloride extended-release tablets whose eGFR later falls below 45 mL/minute/1.73 m<sup>2</sup>, assess the benefit and risk of continuing therapy.</item>
                           <item>
                              <content styleCode="italics">Drug Interactions</content>: The concomitant use of metformin hydrochloride extended-release tablets with specific drugs may increase the risk of metformin­- associated lactic acidosis: those that impair renal function, result in significant hemodynamic change, interfere with acid-base balance or increase metformin accumulation <content styleCode="italics">[see Drug Interactions (<linkHtml href="#DRUG_INTERACTIONS">7</linkHtml>)]. </content>Therefore, consider more frequent monitoring of patients.</item>
                           <item>
                              <content styleCode="italics">Age 65 or Greater:</content> The risk of metformin-associated lactic acidosis increases with the patient’s age because elderly patients have a greater likelihood of having hepatic, renal, or cardiac impairment than younger patients. Assess renal function more frequently in elderly patients <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#GERIATRIC_USE">8.5</linkHtml>)].</content>
                           </item>
                           <item>
                              <content styleCode="italics">Radiological Studies with Contrast:</content> Administration of intravascular iodinated contrast agents in metformin­- treated patients has led to an acute decrease in renal function and the occurrence of lactic acidosis. Stop metformin hydrochloride extended-release tablets at the time of, or prior to, an iodinated contrast imaging procedure in patients with an eGFR between 30 and 60 mL/minute/1.73 m<sup>2</sup>; in patients with a history of hepatic impairment, alcoholism, or heart failure; or in patients who will be administered intra-arterial iodinated contrast. Re-evaluate eGFR 48 hours after the imaging procedure, and restart metformin hydrochloride extended-release tablets if renal function is stable.</item>
                           <item>
                              <content styleCode="italics">Surgery and Other Procedures:</content> Withholding of food and fluids during surgical or other procedures may increase the risk for volume depletion, hypotension and renal impairment. Metformin hydrochloride extended-release tablets should be temporarily discontinued while patients have restricted food and fluid intake.</item>
                           <item>
                              <content styleCode="italics">Hypoxic States:</content> Several of the postmarketing cases of metformin-associated lactic acidosis occurred in the setting of acute congestive heart failure (particularly when accompanied by hypoperfusion and hypoxemia). Cardiovascular collapse (shock), acute myocardial infarction, sepsis, and other conditions associated with hypoxemia have been associated with lactic acidosis and may also cause prerenal azotemia. When such events occur, discontinue metformin hydrochloride extended-release tablets.</item>
                           <item>
                              <content styleCode="italics">Excessive Alcohol Intake:</content> Alcohol potentiates the effect of metformin on lactate metabolism, and this may increase the risk of metformin-associated lactic acidosis. Warn patients against excessive alcohol intake while receiving metformin hydrochloride extended-release tablets.</item>
                           <item>
                              <content styleCode="italics">Hepatic Impairment:</content> Patients with hepatic impairment have developed cases of metformin-associated lactic acidosis. This may be due to impaired lactate clearance resulting in higher lactate blood levels. Therefore, avoid use of metformin hydrochloride extended-release tablets in patients with clinical or laboratory evidence of hepatic disease.</item>
                        </list>
                     </text>
                     <effectiveTime value="20220228"/>
                  </section>
               </component>
               <component>
                  <section ID="_c866af6b-c1c8-f372-93d1-c4da5a4bae52">
                     <id root="a021ca9d-a610-8dc6-873e-d8c8d5472f05"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>5.2 Vitamin B<sub>12</sub> Deficiency</title>
                     <text>
                        <paragraph>In clinical trials of 29-week duration with metformin HCl tablets, a decrease to subnormal levels of previously normal serum vitamin B<sub>12</sub> levels was observed in approximately 7% of patients. Such decrease, possibly due to interference with B<sub>12</sub> absorption from the B<sub>12</sub>-intrinsic factor complex, may be associated with anemia but appears to be rapidly reversible with discontinuation of metformin or vitamin B<sub>12</sub> supplementation. Certain individuals (those with inadequate vitamin B<sub>12</sub> or calcium intake or absorption) appear to be predisposed to developing subnormal vitamin B<sub>12</sub> levels. Measure hematologic parameters on an annual basis and vitamin B<sub>12</sub> at 2 to 3 year intervals in patients on metformin hydrochloride extended-release tablets and manage any abnormalities <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#_04363829-0067-e985-ec55-40a990255852">6.1</linkHtml>)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20190712"/>
                  </section>
               </component>
               <component>
                  <section ID="_0cbe5ec8-7ea8-1dd6-b9c4-a308ea0009d1">
                     <id root="5726130c-fabd-a547-05e0-4fdc42c114c1"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>5.3 Hypoglycemia with Concomitant Use with Insulin and Insulin Secretagogues</title>
                     <text>
                        <paragraph>Insulin and insulin secretagogues (e.g., sulfonylurea) are known to cause hypoglycemia. Metformin hydrochloride extended-release tablets may increase the risk of hypoglycemia when combined with insulin and/or an insulin secretagogue. Therefore, a lower dose of insulin or insulin secretagogue may be required to minimize the risk of hypoglycemia when used in combination with metformin hydrochloride extended-release tablets<content styleCode="italics"> [see Drug Interactions (<linkHtml href="#DRUG_INTERACTIONS">7</linkHtml>)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20190320"/>
                  </section>
               </component>
               <component>
                  <section ID="_d96c379c-b229-ae11-cd6d-6d09e53ba2c9">
                     <id root="83d92af1-6f47-5e94-3e1a-4d5aa321257c"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>5.4 Macrovascular Outcomes</title>
                     <text>
                        <paragraph>There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with metformin hydrochloride extended-release tablets.</paragraph>
                     </text>
                     <effectiveTime value="20190320"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ADVERSE_REACTIONS">
               <id root="7ba268ad-9d25-db24-f000-5841263e0c6c"/>
               <code code="34084-4" displayName="ADVERSE REACTIONS SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The following adverse reactions are discussed in more detail in other sections of the labeling:</paragraph>
                  <paragraph/>
                  <list>
                     <item>Lactic Acidosis <content styleCode="italics">[see Boxed Warning and Warnings and Precautions (<linkHtml href="#_ae6d682f-d855-4b68-f67a-cfba27a7d629">5.1</linkHtml>)]</content>
                     </item>
                     <item>Vitamin B<sub>12</sub> Deficiency <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#_c866af6b-c1c8-f372-93d1-c4da5a4bae52">5.2</linkHtml>)]</content>
                     </item>
                     <item>Hypoglycemia <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#_0cbe5ec8-7ea8-1dd6-b9c4-a308ea0009d1">5.3</linkHtml>)]</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20191010"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Adverse reactions occurring &gt; 5 % in metformin hydrochloride extended-release tablets clinical trials: hypoglycemia, diarrhea, and nausea. (<linkHtml href="#_04363829-0067-e985-ec55-40a990255852">6.1</linkHtml>)  </paragraph>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Apotex Corp. at 1-800-706-5575 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="_04363829-0067-e985-ec55-40a990255852">
                     <id root="4b8d4460-ef82-5fb8-fdb3-a4902b381df0"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>6.1 Clinical Trials Experience</title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</paragraph>
                        <paragraph>In clinical trials conducted in the U.S., over 1,000 patients with type 2 diabetes mellitus have been treated with metformin hydrochloride extended-release tablets 1,500 to 2,000 mg/day in active-controlled and placebo-controlled studies with the 500 mg dosage form. In the add-on to sulfonylurea study, patients receiving background glyburide therapy were randomized to receive add-on treatment of either one of three different regimens of metformin hydrochloride extended-release tablets or placebo. In total, 431 patients received metformin hydrochloride extended-release tablets and glyburide and 144 patients received placebo and glyburide. Adverse reactions reported in greater than 5 % of patients treated with metformin hydrochloride extended-release tablets that were more common in the combined metformin hydrochloride extended-release tablets and glyburide group than in the placebo and glyburide group are shown in Table 1. In 0.7 % of patients treated with metformin hydrochloride extended-release tablets and glyburide, diarrhea was responsible for discontinuation of study medication compared to no patients in the placebo and glyburide group.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Table 1: Adverse Reactions Reported by &gt; 5 %* of Patients for the Combined Metformin Hydrochloride</content> <content styleCode="bold">Extended-Release Tablets Groups Versus Placebo Group</content>
                        </paragraph>
                        <table frame="box" rules="all">
                           <tbody align="center" valign="middle">
                              <tr>
                                 <td>
                                    <content styleCode="bold">Adverse Reaction</content>
                                 </td>
                                 <td align="center">
                                    <content styleCode="bold">Metformin Hydrochloride Extended-<br/>Release Tablets +   Glyburide</content>
                                    <br/>
                                    <content styleCode="bold">(n = 431)</content>
                                 </td>
                                 <td>
                                    <content styleCode="bold">Placebo + Glyburide </content>
                                    <content styleCode="bold">
                                       <br/>(n = 144)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left">   Hypoglycemia   </td>
                                 <td>   14%   </td>
                                 <td>   5%   </td>
                              </tr>
                              <tr>
                                 <td align="left">   Diarrhea   </td>
                                 <td>   13%   </td>
                                 <td>   6%   </td>
                              </tr>
                              <tr>
                                 <td align="left">   Nausea   </td>
                                 <td>   7%   </td>
                                 <td>   4%   </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>*Adverse reactions that were more common in the metformin hydrochloride extended-release tablets -treated than in the placebo-treated patients.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Laboratory Tests</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Vitamin B<sub>12</sub> Concentrations    </content>
                        </paragraph>
                        <paragraph> In clinical trials of 29-week duration with metformin HCl tablets, a decrease to subnormal levels of previously normal serum vitamin B<sub>12</sub> levels was observed in approximately 7 % of patients.</paragraph>
                        <paragraph/>
                        <paragraph/>
                     </text>
                     <effectiveTime value="20190320"/>
                  </section>
               </component>
               <component>
                  <section ID="_8bd5d46d-cd5b-d3f8-fee4-de617eae99a3">
                     <id root="917db2e9-a420-80d1-5673-a712b5c07136"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>6.2 Postmarketing Experience</title>
                     <text>
                        <paragraph>The following adverse reactions have been identified during post-approval use of metformin hydrochloride extended-release tablets. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</paragraph>
                        <paragraph>Cholestatic, hepatocellular, and mixed hepatocellular liver injury have been reported with postmarketing use of metformin.</paragraph>
                     </text>
                     <effectiveTime value="20190320"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="DRUG_INTERACTIONS">
               <id root="3b3c2282-a12d-ea06-425a-63809e82636d"/>
               <code code="34073-7" displayName="DRUG INTERACTIONS SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>7 DRUG INTERACTIONS</title>
               <text>
                  <paragraph>Table 2 presents clinically significant drug interactions with metformin hydrochloride extended-release tablets.   <content styleCode="bold"/>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Table 2: Clinically Significant Drug Interactions with Metformin Hydrochloride Extended-Release Tablets</content>
                  </paragraph>
                  <paragraph/>
                  <table frame="box" rules="all">
                     <tbody>
                        <tr>
                           <td colspan="2">
                              <content styleCode="bold">Carbonic Anhydrase Inhibitors</content>
                           </td>
                        </tr>
                        <tr>
                           <td align="center">
                              <content styleCode="bold"> </content>
                              <content styleCode="bold"> </content>
                              <content styleCode="italics">Clinical Impact</content>: </td>
                           <td> Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with metformin hydrochloride extended-release tablets may increase the risk for lactic acidosis. </td>
                        </tr>
                        <tr>
                           <td align="center">
                              <content styleCode="italics">Intervention</content>: </td>
                           <td> Consider more frequent monitoring of these patients. </td>
                        </tr>
                        <tr>
                           <td>
                              <content styleCode="italics">Examples</content>: </td>
                           <td> Topiramate, zonisamide, acetazolamide or dichlorphenamide. </td>
                        </tr>
                        <tr>
                           <td colspan="2">
                              <content styleCode="bold">Drugs that Reduce Metformin Hydrochloride</content> <content styleCode="bold">Extended-Release Tablets Clearance</content>
                           </td>
                        </tr>
                        <tr>
                           <td align="center">
                              <content styleCode="bold"> </content>
                              <content styleCode="bold"> </content>
                              <content styleCode="italics"> Clinical Impact</content>: </td>
                           <td> Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [<content styleCode="italics">see Clinical Pharmacology (<linkHtml href="#PHARMACOKINETICS">12.3</linkHtml>)</content>]. </td>
                        </tr>
                        <tr>
                           <td>
                              <content styleCode="italics">Intervention</content>: </td>
                           <td> Consider the benefits and risks of concomitant use with metformin hydrochloride extended-release tablets. </td>
                        </tr>
                        <tr>
                           <td>
                              <content styleCode="italics">Examples</content>: </td>
                           <td> Ranolazine, vandetanib, dolutegravir, and cimetidine. </td>
                        </tr>
                        <tr>
                           <td colspan="2">
                              <content styleCode="bold">Alcohol</content>
                           </td>
                        </tr>
                        <tr>
                           <td align="center">
                              <content styleCode="italics">Clinical Impact</content>: </td>
                           <td> Alcohol is known to potentiate the effect of metformin on lactate metabolism. </td>
                        </tr>
                        <tr>
                           <td align="center">
                              <content styleCode="italics">Intervention</content>: </td>
                           <td> Warn patients against excessive alcohol intake while receiving metformin hydrochloride extended-release tablets. </td>
                        </tr>
                        <tr>
                           <td colspan="2">
                              <content styleCode="bold">Insulin Secretagogues or Insulin</content>
                           </td>
                        </tr>
                        <tr>
                           <td align="center">
                              <content styleCode="italics">Clinical Impact</content>: </td>
                           <td> Coadministration of metformin hydrochloride extended-release tablets with an insulin secretagogue (e.g., sulfonylurea) or insulin may increase the risk of hypoglycemia. </td>
                        </tr>
                        <tr>
                           <td>
                              <content styleCode="italics">Intervention</content>: </td>
                           <td> Patients receiving an insulin secretagogue or insulin may require lower doses of the insulin secretagogue or insulin. </td>
                        </tr>
                        <tr>
                           <td colspan="2">
                              <content styleCode="bold">Drugs Affecting Glycemic Control</content>
                           </td>
                        </tr>
                        <tr>
                           <td align="center">
                              <content styleCode="bold"> </content>
                              <content styleCode="italics"> Clinical Impact</content>: </td>
                           <td> Certain drugs tend to produce hyperglycemia and may lead to loss of glycemic control. </td>
                        </tr>
                        <tr>
                           <td>
                              <content styleCode="italics">Intervention</content>: </td>
                           <td> When such drugs are administered to a patient receiving metformin hydrochloride extended-release tablets, observe the patient closely for loss of blood glucose control. When such drugs are withdrawn from a patient receiving metformin hydrochloride extended-release tablets, observe the patient closely for hypoglycemia. </td>
                        </tr>
                        <tr>
                           <td>
                              <content styleCode="bold"> </content>
                              <content styleCode="italics"> Examples</content>: </td>
                           <td> Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers, and isoniazid. </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph/>
                  <paragraph/>
                  <paragraph/>
               </text>
               <effectiveTime value="20191010"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph/>
                        <list>
                           <item>Carbonic anhydrase inhibitors may increase risk of lactic acidosis. Consider more frequent monitoring. <linkHtml href="#DRUG_INTERACTIONS">(7)</linkHtml>
                           </item>
                           <item>Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine) may increase the accumulation of metformin. Consider the benefits and risks of concomitant use. (<linkHtml href="#DRUG_INTERACTIONS">7</linkHtml>)</item>
                           <item>Alcohol can potentiate the effect of metformin on lactate metabolism. Warn patients against excessive alcohol intake. (<linkHtml href="#DRUG_INTERACTIONS">7</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="USE_IN_SPECIFIC_POPULATIONS">
               <id root="6317448e-7f18-e5f1-206f-3fdd23ec308d"/>
               <code code="43684-0" displayName="USE IN SPECIFIC POPULATIONS SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <text>
                  <paragraph/>
               </text>
               <effectiveTime value="20191010"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph/>
                        <list>
                           <item>Females and Males of Reproductive Potential: Advise premenopausal females of the potential for an unintended pregnancy. (<linkHtml href="#NURSING_MOTHERS">8.3</linkHtml>)</item>
                           <item>Geriatric Use: Assess renal function more frequently. <linkHtml href="#GERIATRIC_USE">(8.5)</linkHtml>
                           </item>
                           <item>Hepatic Impairment: Avoid use in patients with hepatic impairment.<linkHtml href="#_b08e83b4-b0dc-7ba1-5d08-c7c2b228ecbb"> (8.7)</linkHtml>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="PREGNANCY">
                     <id root="bdcbfa9f-b4d7-234f-cc66-71db2324d349"/>
                     <code code="42228-7" displayName="PREGNANCY SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>8.1 Pregnancy</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>Limited data with metformin hydrochloride extended-release tablets in pregnant women are not sufficient to determine a drug-associated risk for major birth defects or miscarriage. Published studies with metformin use during pregnancy have not reported a clear association with metformin and major birth defect or miscarriage risk <content styleCode="italics">[see Data]</content>. There are risks to the mother and fetus associated with poorly controlled diabetes mellitus in pregnancy<content styleCode="italics"> [see Clinical Considerations].</content>
                        </paragraph>
                        <paragraph>No adverse developmental effects were observed when metformin was administered to pregnant Sprague Dawley rats and rabbits during the period of organogenesis at doses up to 3 and 1 times, respectively, a 2,000 mg clinical dose, based on body surface area <content styleCode="italics">[see Data]. </content>
                        </paragraph>
                        <paragraph/>
                        <paragraph> The estimated background risk of major birth defects is 6 to 10 % in women with pregestational diabetes mellitus with an HbA1c &gt; 7 and has been reported to be as high as 20 to 25 % in women with an HbA1c &gt; 10. The estimated background risk of miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4 % and 15 to 20 %, respectively.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Clinical Considerations</content>   </paragraph>
                        <paragraph>
                           <content styleCode="italics">Disease-associated maternal and/or embryo/fetal risk</content>
                        </paragraph>
                        <paragraph>Poorly controlled diabetes mellitus in pregnancy increases the maternal risk for diabetic ketoacidosis, pre-eclampsia, spontaneous abortions, preterm delivery, stillbirth and delivery complications. Poorly controlled diabetes mellitus increases the fetal risk for major birth defects, stillbirth, and macrosomia-related morbidity.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Data   </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics"> Human Data </content>
                        </paragraph>
                        <paragraph>Published data from post-marketing studies have not reported a clear association with metformin and major birth defects, miscarriage, or adverse maternal or fetal outcomes when metformin was used during pregnancy. However, these studies cannot definitely establish the absence of any metformin-associated risk because of methodological limitations, including small sample size and inconsistent comparator groups.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Animal Data </content>
                        </paragraph>
                        <paragraph> Metformin HCl was not teratogenic or embyrolethal when administered to rats prior to pregnancy through the period of organogenesis at doses up to 900 mg/kg, or when administered to rabbits during the period of organogenesis at doses up to 90 mg/kg.</paragraph>
                        <paragraph/>
                     </text>
                     <effectiveTime value="20191010"/>
                  </section>
               </component>
               <component>
                  <section ID="LABOR_AND_DELIVERY">
                     <id root="ad4cacda-f6ef-bd73-9a42-77f793f997a2"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary </content>  </paragraph>
                        <paragraph>Limited published studies report that metformin is present in human milk <content styleCode="italics">[see Data]</content>. However, there is insufficient information to determine the effects of metformin on the breastfed infant and no available information on the effects of metformin on milk production. Therefore, the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for metformin hydrochloride extended-release tablets and any potential adverse effects on the breastfed child from metformin hydrochloride extended-release tablets or from the underlying maternal condition.   </paragraph>
                        <paragraph>
                           <content styleCode="underline">Data </content>  </paragraph>
                        <paragraph> Published clinical lactation studies report that metformin is present in human milk which resulted in infant doses approximately 0.11 % to 1 % of the maternal weight-adjusted dosage and a milk/plasma ratio ranging between 0.13 and 1. However, the studies were not designed to definitely establish the risk of use of metformin during lactation because of small sample size and limited adverse event data collected in infants.</paragraph>
                     </text>
                     <effectiveTime value="20191010"/>
                  </section>
               </component>
               <component>
                  <section ID="NURSING_MOTHERS">
                     <id root="f4167ef4-d723-9986-74a0-09277f40ece0"/>
                     <code code="77291-3" codeSystem="2.16.840.1.113883.6.1" displayName="FEMALES &amp; MALES OF REPRODUCTIVE POTENTIAL SECTION"/>
                     <title>8.3 Females and Males of Reproductive Potential</title>
                     <text>
                        <paragraph>Discuss the potential for unintended pregnancy with premenopausal women as therapy with metformin hydrochloride extended-release tablets may result in ovulation in some anovulatory women.</paragraph>
                     </text>
                     <effectiveTime value="20190320"/>
                  </section>
               </component>
               <component>
                  <section ID="PEDIATRIC_USE">
                     <id root="4012cf52-70ba-84f3-ef88-3754871587cc"/>
                     <code code="34081-0" displayName="PEDIATRIC USE SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>Safety and effectiveness of metformin hydrochloride extended-release tablets in pediatric patients have not been established.</paragraph>
                     </text>
                     <effectiveTime value="20190320"/>
                  </section>
               </component>
               <component>
                  <section ID="GERIATRIC_USE">
                     <id root="462f8d60-4c8a-d038-e649-3172f84e6076"/>
                     <code code="34082-8" displayName="GERIATRIC USE SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>Clinical studies of metformin hydrochloride extended-release tablets did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy and the higher risk of lactic acidosis. Assess renal function more frequently in elderly patients. <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#_b5699d37-b2b7-e4fe-d783-b8faa8313f77">2.2</linkHtml>) and Warnings and Precautions (<linkHtml href="#_ae6d682f-d855-4b68-f67a-cfba27a7d629">5.1</linkHtml>).]</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20190320"/>
                  </section>
               </component>
               <component>
                  <section ID="_1701e714-b0f7-afef-21e4-2f1dd815caac">
                     <id root="db24caeb-43a0-dc68-d014-0cb673f1f6ff"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>8.6 Renal Impairment</title>
                     <text>
                        <paragraph>Metformin is substantially excreted by the kidney, and the risk of metformin accumulation and lactic acidosis increases with the degree of renal impairment. Metformin hydrochloride extended-release tablets are contraindicated in severe renal impairment, patients with an estimated glomerular filtration rate (eGFR) below 30 mL/minute/1.73 m<sup>2</sup>.<content styleCode="italics"> [see Dosage and Administration (<linkHtml href="#_b5699d37-b2b7-e4fe-d783-b8faa8313f77">2.2</linkHtml>), Contraindications (<linkHtml href="#CONTRAINDICATIONS">4</linkHtml>), Warnings and Precautions (<linkHtml href="#_ae6d682f-d855-4b68-f67a-cfba27a7d629">5.1</linkHtml>), and Clinical Pharmacology (<linkHtml href="#PHARMACOKINETICS">12.3</linkHtml>).]</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20190320"/>
                  </section>
               </component>
               <component>
                  <section ID="_b08e83b4-b0dc-7ba1-5d08-c7c2b228ecbb">
                     <id root="60206344-1dd6-e1e4-fac2-88e6804569ea"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>8.7 Hepatic Impairment</title>
                     <text>
                        <paragraph>Use of metformin in patients with hepatic impairment has been associated with some cases of lactic acidosis. Metformin hydrochloride extended-release tablets are not recommended in patients with hepatic impairment.<content styleCode="italics"> [see Warnings and Precautions (<linkHtml href="#_ae6d682f-d855-4b68-f67a-cfba27a7d629">5.1</linkHtml>).]</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20190320"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="OVERDOSAGE">
               <id root="ecef877c-29b8-dc21-8d69-65dd043844c0"/>
               <code code="34088-5" displayName="OVERDOSAGE SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>10 OVERDOSAGE</title>
               <text>
                  <paragraph>Overdose of metformin HCl has occurred, including ingestion of amounts greater than 50 grams. Hypoglycemia was reported in approximately 10 % of cases, but no causal association with metformin has been established. Lactic acidosis has been reported in approximately 32 % of metformin overdose cases.<content styleCode="italics"> [see Warnings and Precautions (<linkHtml href="#_ae6d682f-d855-4b68-f67a-cfba27a7d629">5.1</linkHtml>).] </content>Metformin is dialyzable with a clearance of up to 170 mL/minute under good hemodynamic conditions. Therefore, hemodialysis may be useful for removal of accumulated drug from patients in whom metformin overdosage is suspected.</paragraph>
               </text>
               <effectiveTime value="20191010"/>
            </section>
         </component>
         <component>
            <section ID="DESCRIPTION">
               <id root="c94c5162-ba35-bb8e-f73b-a78146acedda"/>
               <code code="34089-3" displayName="DESCRIPTION SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>Metformin hydrochloride extended-release tablets, USP contains the biguanide antihyperglycemic agent metformin in the form of monohydrochloride salt. The chemical name of metformin hydrochloride is Imidodicarbonimidic diamide, N.N-dimethyl-monohydrochloride. The structural formula is as shown:</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM346065517862"/>
                  </paragraph>
                  <paragraph>Metformin hydrochloride, USP is a white or almost white powder with a molecular formula of C<sub>4</sub>H<sub>11</sub>N<sub>5</sub>•HCl and a molecular weight of 165.62 g/mol. Metformin hydrochloride is freely soluble in water; slightly soluble in alcohol; practically insoluble in acetone, chloroform, ether, and methylene chloride. The pKa of metformin is 12.4. The pH of a 1% aqueous solution of metformin hydrochloride is 6.68.</paragraph>
                  <paragraph>Metformin hydrochloride extended-release tablets, USP contain 500 mg or 1,000 mg of metformin hydrochloride, which is equivalent to 389.93 mg or 779.86 mg metformin, respectively. Each 500 mg and 1,000 mg tablet contains carbomer homopolymer type A, carbomer homopolymer type B, dibasic calcium phosphate, dibutyl sebacate, ethylcellulose, hypromellose and magnesium stearate.</paragraph>
                  <paragraph>Meets USP dissolution test 20.<content styleCode="none"> </content>
                  </paragraph>
               </text>
               <effectiveTime value="20220228"/>
            </section>
         </component>
         <component>
            <section ID="CLINICAL_PHARMACOLOGY">
               <id root="9a53c03e-af52-8468-27ab-a482cc587437"/>
               <code code="34090-1" displayName="CLINICAL PHARMACOLOGY SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <text/>
               <effectiveTime value="20191010"/>
               <component>
                  <section ID="MECHANISM_OF_ACTION">
                     <id root="ba3b2959-acb9-2eab-ea6b-a5db47c7944d"/>
                     <code code="43679-0" displayName="MECHANISM OF ACTION SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>Metformin is a biguanide that improves glucose tolerance in patients with type 2 diabetes, lowering both basal and postprandial plasma glucose. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization. With metformin therapy, insulin secretion remains unchanged while fasting insulin levels and day-long plasma insulin response may decrease.</paragraph>
                     </text>
                     <effectiveTime value="20190320"/>
                  </section>
               </component>
               <component>
                  <section ID="PHARMACOKINETICS">
                     <id root="fa9b5961-51b1-1e66-aa2f-e0bc74619d99"/>
                     <code code="43682-4" displayName="PHARMACOKINETICS SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph>
                           <content styleCode="bold italics">Absorption</content>
                        </paragraph>
                        <paragraph>Following a single oral dose of 1,000 mg (2 x 500 mg tablets) metformin hydrochloride extended-release tablets after a meal, the time to reach maximum plasma metformin concentration (T<sub>max</sub>) is achieved at approximately 7 to 8 hours. In both single- and multiple-dose studies in healthy subjects, once daily 1,000 mg (2 x 500 mg tablets) dosing provides equivalent systemic exposure, as measured by area under the curve (AUC), and up to 35 % higher C<sub>max</sub>, of metformin relative to the immediate-release given as 500 mg twice daily. At usual clinical doses and dosing schedules of metformin, steady state plasma concentrations of metformin are reached within 24 to 48 hours and are generally &lt; 1 mcg/mL.</paragraph>
                        <paragraph>In a two-way, single-dose, crossover study in healthy volunteers, the 1,000 mg tablet was found to be similar to two 500 mg tablets under fed conditions based on equivalent C<sub>max</sub> and AUCs for the two formulations.</paragraph>
                        <paragraph>Single oral doses of metformin hydrochloride extended-release tablets from 500 mg to 2,500 mg resulted in less than proportional increase in both AUC and C<sub>max</sub>.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Effect of food: </content>Low-fat and high-fat meals increased the systemic exposure (as measured by AUC) from metformin hydrochloride extended-release tablets by about 38 % and 73 %, respectively, relative to fasting. Both meals prolonged metformin T<sub>max</sub> by approximately 3 hours but C<sub>max</sub> was not affected.</paragraph>
                        <paragraph>
                           <content styleCode="bold italics">Distribution</content>
                        </paragraph>
                        <paragraph>The apparent volume of distribution (V/F) of metformin following single oral doses of 850 mg metformin HCl averaged 654±358 L. Metformin is negligibly bound to plasma proteins. Metformin partitions into erythrocytes, most likely as a function of time.</paragraph>
                        <paragraph>
                           <content styleCode="bold italics">Metabolism</content>
                        </paragraph>
                        <paragraph>Intravenous, single-dose studies in healthy subjects demonstrate that metformin is excreted unchanged in the urine and does not undergo hepatic metabolism (no metabolites have been identified in humans), nor biliary excretion.</paragraph>
                        <paragraph>
                           <content styleCode="bold italics">Excretion</content>
                        </paragraph>
                        <paragraph> Renal clearance is approximately 3.5 times greater than creatinine clearance, which indicates that tubular secretion is the major route of metformin elimination. Following oral administration, approximately 90 % of the absorbed drug is eliminated via the renal route within the first 24 hours, with a plasma elimination half-life of approximately 6.2 hours. In blood, the elimination half-life is approximately 17.6 hours, suggesting that the erythrocyte mass may be a compartment of distribution.</paragraph>
                        <paragraph>
                           <content styleCode="bold italics"/>
                           <content styleCode="bold">Special Populations</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold italics">Renal Impairment</content>
                        </paragraph>
                        <paragraph>Following a single-dose administration of metformin hydrochloride extended-release tablets 500 mg in subjects with mild and moderate renal impairment, the oral and renal clearance of metformin were decreased by 33 % and 50 % and 16 % and 53 %, respectively. Metformin peak and systemic exposure was 27 % and 61 % greater, respectively in subjects with mild renal impairment and 74 % and 2.36-fold greater in subjects with moderate renal impairment as compared to healthy subjects. <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#_b5699d37-b2b7-e4fe-d783-b8faa8313f77">2.2</linkHtml>), Contraindications (<linkHtml href="#CONTRAINDICATIONS">4</linkHtml>), and Warnings and Precautions (<linkHtml href="#_ae6d682f-d855-4b68-f67a-cfba27a7d629">5.1</linkHtml>).]</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold italics">Hepatic Impairment</content>
                        </paragraph>
                        <paragraph> No pharmacokinetic studies of metformin hydrochloride extended-release tablets have been conducted in subjects with hepatic impairment, <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#_ae6d682f-d855-4b68-f67a-cfba27a7d629">5.1</linkHtml>) and Use in Specific Populations (<linkHtml href="#_b08e83b4-b0dc-7ba1-5d08-c7c2b228ecbb">8.7</linkHtml>)]</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold italics">Geriatrics</content>
                        </paragraph>
                        <paragraph> Limited data from controlled pharmacokinetic studies of metformin HCl in healthy elderly subjects suggest that total plasma clearance of metformin is decreased by 35 %, the half-life is prolonged by 64 % and C<sub>max</sub> is increased by 76 %, compared to healthy young subjects. From these data, it appears that the change in metformin pharmacokinetics with aging is primarily accounted for by a change in renal function. <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#DOSAGE_AND_ADMINISTRATION">2</linkHtml>) and Warnings and Precautions (<linkHtml href="#_ae6d682f-d855-4b68-f67a-cfba27a7d629">5.1</linkHtml>).]</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold italics">Gender</content>
                        </paragraph>
                        <paragraph> In the pharmacokinetic studies in healthy volunteers, there were no important differences between male and female subjects with respect to metformin AUC and t<sub>1/2</sub>. However, C<sub>max</sub> for metformin was 40 % higher in female subjects as compared to males. In controlled clinical studies in patients with type 2 diabetes, the antihyperglycemic effect of metformin HCl tablets was comparable in males and females. The gender differences for C<sub>max</sub> are unlikely to be clinically important.   <content styleCode="bold italics"/>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold italics">Race</content>
                        </paragraph>
                        <paragraph> A trend towards 10 % higher metformin C<sub>max</sub> and AUC values for metformin are obtained in Asian subjects when compared to Caucasian, Hispanic and Black subjects. The differences between the Asian and Caucasian groups are unlikely to be clinically important. In controlled clinical studies of metformin HCl in patients with type 2 diabetes, the antihyperglycemic effect was comparable in whites (n = 249), blacks (n = 51) and Hispanics (n = 24).   <content styleCode="bold italics"/>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold italics">Pediatrics</content>
                        </paragraph>
                        <paragraph> There are no available pharmacokinetic data with metformin hydrochloride extended-release tablets in pediatric patients.   <content styleCode="bold italics"/>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold italics">Drug Interactions</content>
                        </paragraph>
                        <paragraph> Specific pharmacokinetic drug interaction studies with metformin hydrochloride extended-release tablets have not been performed except for one with glyburide. However, such studies have been performed on metformin HCl tablets.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Table 3: Effect of Coadministered Drug on Plasma Metformin Systemic Exposure</content>
                        </paragraph>
                        <table frame="box" rules="all">
                           <tbody align="center">
                              <tr>
                                 <td rowspan="2">
                                    <content styleCode="bold">Coadministered </content>
                                    <content styleCode="bold">Drug</content>
                                 </td>
                                 <td colspan="2" rowspan="2">
                                    <content styleCode="bold">Dose of Coadministered Drug<sup>1</sup>
                                    </content>
                                 </td>
                                 <td colspan="2" rowspan="2">
                                    <content styleCode="bold">Dose of Metformin HCl<sup>1</sup>
                                    </content>
                                 </td>
                                 <td colspan="3">
                                    <content styleCode="bold">Geometric Mean Ratio (ratio with/ <br/>without coadministered drug)</content>
                                    <content styleCode="bold">
                                       <br/>No Effect = 1.00</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="2">
                                    <content styleCode="bold">AUC<sup>2</sup>
                                    </content>
                                 </td>
                                 <td>
                                    <content styleCode="bold">C</content>
                                    <sub>max</sub>
                                    <content styleCode="bold"/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="8"> No dosing adjustments required for the following: </td>
                              </tr>
                              <tr>
                                 <td align="left"> Glyburide </td>
                                 <td colspan="2"> 5 mg </td>
                                 <td colspan="2"> 500 mg<sup>4</sup>
                                 </td>
                                 <td colspan="2"> 0.98<sup>3</sup>
                                 </td>
                                 <td> 0.99<sup>3</sup>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left"> Furosemide </td>
                                 <td colspan="2"> 40 mg </td>
                                 <td colspan="2"> 850 mg </td>
                                 <td colspan="2"> 1.09<sup>3</sup>
                                 </td>
                                 <td> 1.22<sup>3</sup>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left"> Nifedipine </td>
                                 <td colspan="2"> 10 mg </td>
                                 <td colspan="2"> 850 mg </td>
                                 <td colspan="2"> 1.16 </td>
                                 <td> 1.21 </td>
                              </tr>
                              <tr>
                                 <td align="left"> Propranolol </td>
                                 <td colspan="2"> 40 mg </td>
                                 <td colspan="2"> 850 mg </td>
                                 <td colspan="2"> 0.90 </td>
                                 <td> 0.94 </td>
                              </tr>
                              <tr>
                                 <td align="left"> Ibuprofen </td>
                                 <td colspan="2"> 400 mg </td>
                                 <td colspan="2"> 850 mg </td>
                                 <td colspan="2"> 1.05<sup>3</sup>
                                 </td>
                                 <td> 1.07<sup>3</sup>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="8">
                                    <content styleCode="bold">Cationic drugs that are eliminated by renal tubular secretion may increase the accumulation of metformin: </content>
                                    <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#_ae6d682f-d855-4b68-f67a-cfba27a7d629">5.1</linkHtml>) and Drug Interactions (<linkHtml href="#DRUG_INTERACTIONS">7</linkHtml>)]</content>. </td>
                              </tr>
                              <tr>
                                 <td> Cimetidine </td>
                                 <td> 400 mg </td>
                                 <td colspan="2"> 850 mg </td>
                                 <td colspan="2"> 1.40 </td>
                                 <td colspan="2"> 1.61 </td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="8">
                                    <content styleCode="bold">Carbonic anhydrase inhibitors may cause metabolic acidosis:</content>
                                    <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#_ae6d682f-d855-4b68-f67a-cfba27a7d629">5.1</linkHtml>) and Drug Interactions (<linkHtml href="#DRUG_INTERACTIONS">7</linkHtml>)]</content>. </td>
                              </tr>
                              <tr>
                                 <td align="left"> Topiramate </td>
                                 <td> 100 mg<sup>5</sup>
                                 </td>
                                 <td colspan="2"> 500 mg<sup>5</sup>
                                 </td>
                                 <td colspan="2"> 1.25<sup>5</sup>
                                 </td>
                                 <td colspan="2"> 1.17 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <sup>1</sup>All metformin HCl and coadministered drugs were given as single doses. </paragraph>
                        <paragraph>
                           <sup>2</sup>AUC=AUC<sub>0-inf</sub>
                           <sup/>
                        </paragraph>
                        <paragraph>
                           <sup>3</sup>Ratio of arithmetic means <sup/>
                        </paragraph>
                        <paragraph>
                           <sup>4</sup>Metformin hydrochloride extended-release tablets 500 mg <sup/>
                        </paragraph>
                        <paragraph>
                           <sup>5</sup>At steady state with topiramate 100 mg every 12 hours and metformin 500 mg every 12 hours; AUC = AUC<sub>0-12h</sub>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">Table 4: Effect of Metformin on Coadministered Drug Systemic Exposure</content>
                        </paragraph>
                        <table frame="box" rules="all">
                           <tbody align="center" valign="middle">
                              <tr>
                                 <td rowspan="2">
                                    <content styleCode="bold">Coadministered </content>
                                    <content styleCode="bold">Drug</content>
                                 </td>
                                 <td rowspan="2">
                                    <content styleCode="bold">Dose of Coadministered Drug</content>
                                    <sup>1</sup>
                                    <content styleCode="bold"/>
                                 </td>
                                 <td rowspan="2">
                                    <content styleCode="bold">Dose of Metformin HCl</content>
                                    <sup>1</sup>
                                    <content styleCode="bold"/>
                                 </td>
                                 <td colspan="2">
                                    <content styleCode="bold">Geometric Mean Ratio (ratio with/ without coadministered drug)</content>
                                    <content styleCode="bold">No effect = 1.00</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td>
                                    <content styleCode="bold">AUC</content>
                                    <sup>2</sup>
                                    <content styleCode="bold"/>
                                 </td>
                                 <td>
                                    <content styleCode="bold">C</content>
                                    <sub>max</sub>
                                    <content styleCode="bold"/>
                                 </td>
                              </tr>
                              <tr align="left">
                                 <td colspan="5"> No dosing adjustments required for the following: </td>
                              </tr>
                              <tr>
                                 <td align="left"> Glyburide </td>
                                 <td> 5 mg </td>
                                 <td> 500 mg<sup>4</sup>
                                 </td>
                                 <td> 0.78<sup>3</sup>
                                 </td>
                                 <td> 0.63<sup>3</sup>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left"> Furosemide </td>
                                 <td> 40 mg </td>
                                 <td> 850 mg </td>
                                 <td> 0.87<sup>3</sup>
                                 </td>
                                 <td> 0.69<sup>3</sup>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left"> Nifedipine </td>
                                 <td> 10 mg </td>
                                 <td> 850 mg </td>
                                 <td> 1.10<sup>4</sup>
                                 </td>
                                 <td> 1.08 </td>
                              </tr>
                              <tr>
                                 <td align="left"> Propranolol </td>
                                 <td> 40 mg </td>
                                 <td> 850 mg </td>
                                 <td> 1.01<sup>4</sup>
                                 </td>
                                 <td> 0.94 </td>
                              </tr>
                              <tr>
                                 <td align="left"> Ibuprofen </td>
                                 <td> 400 mg </td>
                                 <td> 850 mg </td>
                                 <td> 0.97<sup>5</sup>
                                 </td>
                                 <td> 1.01<sup>5</sup>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left"> Cimetidine </td>
                                 <td> 400 mg </td>
                                 <td> 850 mg </td>
                                 <td> 0.95<sup>4</sup>
                                 </td>
                                 <td> 1.01 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <sup>1</sup>All metformin HCl and coadministered drugs were given as single doses. <sup/>
                        </paragraph>
                        <paragraph>
                           <sup>2</sup>AUC=AUC<sub>0–inf</sub> unless otherwise noted <sup/>
                        </paragraph>
                        <paragraph>
                           <sup>3</sup>Ratio of arithmetic means, p-value of difference &lt;0.05 </paragraph>
                        <paragraph>
                           <sup>4</sup>AUC<sub>0-24 hr</sub> reported </paragraph>
                        <paragraph>
                           <sup>5</sup>Ratio of arithmetic means</paragraph>
                        <paragraph/>
                        <paragraph/>
                     </text>
                     <effectiveTime value="20191010"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="NONCLINICAL_TOXICOLOGY">
               <id root="940a9bf8-82d6-632c-fe5b-77482ba3adc8"/>
               <code code="43680-8" displayName="NONCLINICAL TOXICOLOGY SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <text/>
               <effectiveTime value="20191010"/>
               <component>
                  <section ID="CARCINOGENESIS_AND_MUTAGENESIS_AND_IMPAIRMENT_OF_FERTILITY">
                     <id root="1b6a4c46-695f-9ad9-7d76-f7d85178ff00"/>
                     <code code="34083-6" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>Long-term carcinogenicity studies have been performed in Sprague Dawley rats at doses of 150, 300, and 450 mg/kg/day in males and 150, 450, 900, and 1,200 mg/kg/day in females. These doses are approximately 2, 4, and 8 times in males, and 3, 7, 12, and 16 times in females of the maximum recommended human daily dose of 2,000 mg based on body surface area comparisons. No evidence of carcinogenicity with metformin was found in either male or female rats. A carcinogenicity study was also performed in Tg.AC transgenic mice at doses up to 2,000 mg applied dermally. No evidence of carcinogenicity was observed in male or female mice.   </paragraph>
                        <paragraph> Genotoxicity assessments in the Ames test, gene mutation test (mouse lymphoma cells), chromosomal aberrations test (human lymphocytes) and <content styleCode="italics">in vivo</content> mouse micronucleus tests were negative. Fertility of male or female rats was not affected by metformin when administered at doses up to 600 mg/kg/day, which is approximately 3 times the maximum recommended human daily dose based on body surface area comparisons.</paragraph>
                     </text>
                     <effectiveTime value="20191010"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="CLINICAL_STUDIES">
               <id root="7cc3af15-9c32-830c-03d1-c7c542e2692e"/>
               <code code="34092-7" displayName="CLINICAL STUDIES SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>14 CLINICAL STUDIES</title>
               <text>
                  <paragraph>In a multicenter, randomized, double-blind, active-controlled, dose-ranging, parallel group study conducted in patients type 2 diabetes mellitus, metformin hydrochloride extended-release tablets 1,500 mg once daily, metformin hydrochloride extended-release tablets 1,500 per day in divided doses (500 mg in the morning and 1,000 mg in the evening), and metformin hydrochloride extended-release tablets 2,000 mg once daily were compared to immediate-release metformin HCl tablets 1,500 mg per day in divided doses (500 mg in the morning and 1,000 mg in the evening). This study included patients (n = 338) who were newly diagnosed with diabetes, patients treated only with diet and exercise, patients treated with a single antidiabetic medication (sulfonylureas, alpha-glucosidase inhibitors, thiazolidinediones, or meglitinides), and patients (n = 368) receiving metformin HCl tablets up to 1,500 mg/day plus a sulfonylurea at a dose equal to or less than one-half the maximum dose. Patients who were enrolled on monotherapy or combination antidiabetic therapy underwent a 6 - week washout. Patients randomized to metformin hydrochloride extended-release tablets began titration from 1,000 mg/day up to their assigned treatment dose over 3 weeks. Patients randomized to immediate-release metformin initiated 500 mg twice daily for 1 week followed by 500 mg with breakfast and 1,000 mg with dinner for the second week. The 3-week treatment period was followed by an additional 21-week period at the randomized dose. The results are presented in Table 5.   <content styleCode="bold"/>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Table 5: Mean Changes from Baseline in HbA1c and Fasting Plasma Glucose at Week 24 Comparing Metformin Hydrochloride</content> <content styleCode="bold">Extended-Release Tablets versus Metformin HCl Tablets* in Patients with Type 2 Diabetes Mellitus</content>
                  </paragraph>
                  <table frame="box" rules="all">
                     <tbody align="center">
                        <tr>
                           <td rowspan="2">   </td>
                           <td colspan="3">
                              <content styleCode="bold">Metformin Hydrochloride Extended-Release Tablets</content>
                           </td>
                           <td rowspan="2">
                              <content styleCode="bold">Metformin HCl Tablets*</content>
                              <content styleCode="bold">1,500 mg in Divided Doses </content>
                              <content styleCode="bold">(n = 174)</content>
                           </td>
                        </tr>
                        <tr>
                           <td>
                              <content styleCode="bold">1,500 mg</content>
                              <content styleCode="bold">Once Daily </content>
                              <content styleCode="bold">(n = 178)</content>
                           </td>
                           <td>
                              <content styleCode="bold">1,500 mg</content>
                              <content styleCode="bold">in Divided Doses</content>
                              <content styleCode="bold">(n = 182)</content>
                           </td>
                           <td>
                              <content styleCode="bold">2,000 mg</content>
                              <content styleCode="bold">Once Daily </content>
                              <content styleCode="bold">(n =1 72)</content>
                           </td>
                        </tr>
                        <tr>
                           <td align="left">
                              <content styleCode="bold">HbA1c (%), N</content>
                           </td>
                           <td> 169 </td>
                           <td> 175 </td>
                           <td> 159 </td>
                           <td> 170 </td>
                        </tr>
                        <tr>
                           <td align="left"> Baseline </td>
                           <td> 8.2 </td>
                           <td> 8.5 </td>
                           <td> 8.3 </td>
                           <td> 8.7 </td>
                        </tr>
                        <tr>
                           <td align="left"> Mean Change at Final Visit </td>
                           <td> -0.7 </td>
                           <td> -0.7 </td>
                           <td> -1.1 </td>
                           <td> -0.7 </td>
                        </tr>
                        <tr>
                           <td align="left"> Mean Difference from Metformin HCl Tablets* (98.4% CI) </td>
                           <td> 0 (-0.3, 0.3) </td>
                           <td> 0 (-0.3, 0.3) </td>
                           <td> -0.4 (-0,7, -0.1) </td>
                           <td> N/A </td>
                        </tr>
                        <tr>
                           <td align="left">
                              <content styleCode="bold">Fasting Plasma Glucose</content>
                              <content styleCode="bold">(mg/dL), N</content>
                           </td>
                           <td> 175 </td>
                           <td> 179 </td>
                           <td> 170 </td>
                           <td> 172 </td>
                        </tr>
                        <tr>
                           <td align="left"> Baseline </td>
                           <td> 190 </td>
                           <td> 192.3 </td>
                           <td> 184 </td>
                           <td> 197 </td>
                        </tr>
                        <tr>
                           <td align="left"> Mean Change at Final Visit </td>
                           <td> -39 </td>
                           <td> -32 </td>
                           <td> -42 </td>
                           <td> -32 </td>
                        </tr>
                        <tr>
                           <td align="left"> Mean Difference from Metformin HCl Tablets* (95% CI) </td>
                           <td>
                              <content styleCode="bold"> </content> -6 (-15, 2) </td>
                           <td>
                              <content styleCode="bold"> </content> 0 (-8, 9) </td>
                           <td>
                              <content styleCode="bold"> </content> -10 (-19, -1) </td>
                           <td>
                              <content styleCode="bold"> </content> N/A </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>*Immediate-release metformin HCl tablets</paragraph>
                  <paragraph>Mean baseline body weight was 88.2 kg, 90.5 kg, 87.7 kg and 88.7 kg in the metformin hydrochloride extended-release tablets 1,500 mg once daily, metformin hydrochloride extended-release tablets 1,500 mg in divided doses, metformin hydrochloride extended-release tablets 2,000 mg once daily and metformin HCl tablets 1,500 mg in divided doses arms, respectively. Mean change in body weight from baseline to week 24 was -0.9 kg, -0.7 kg, -1.1 kg, and -0.9 kg in the metformin hydrochloride extended-release tablets 1,500 mg once daily, metformin hydrochloride extended-release tablets 1,500 mg in divided doses, metformin hydrochloride extended-release tablets 2,000 mg once daily and metformin HCl tablets 1,500 mg in divided doses arms, respectively.</paragraph>
                  <paragraph>A double-blind, randomized, placebo-controlled (glyburide add-on) multicenter study enrolled patients with type 2 diabetes mellitus who were newly diagnosed or treated with diet and exercise (n = 144), or who were receiving monotherapy with metformin, sulfonylureas, alpha-glucosidase inhibitors, thiazolidinediones, or meglitinides, or treated with combination therapy consisting of metformin HCl/glyburide at doses up to 1,000 mg metformin + 10 mg glyburide per day (or equivalent doses of glipizide or glimepiride up to half the maximum therapeutic dose) (n = 431). All patients were stabilized on glyburide for a 6-week run-in period, and then randomized to 1 of 4 treatments: placebo + glyburide (glyburide alone); metformin hydrochloride extended-release tablets 1,500 mg once a day + glyburide, metformin hydrochloride extended-release tablets 2,000 mg once a day + glyburide, or metformin hydrochloride extended-release tablets 1,000 mg twice a day + glyburide. A 3-week metformin hydrochloride extended-release tablets titration period was followed by a 21-week maintenance treatment period. Use of insulin and oral hypoglycemic agents other than the study drugs were prohibited. The results are <content styleCode="bold">presented in Table 6.</content>
                     <content styleCode="bold"> </content>
                     <content styleCode="bold"/>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Table 6: Mean Changes from Baseline in HbA1c and Fasting Plasma Glucose at Week 24 for the Metformin Hydrochloride Extended-Release Tablets + Glyburide Groups and Placebo+ Glyburide Treatment Group in Patients with Type 2 Diabetes Mellitus</content>
                  </paragraph>
                  <table frame="box" rules="all">
                     <tbody align="center">
                        <tr>
                           <td rowspan="2">       </td>
                           <td colspan="3">
                              <content styleCode="bold">Metformin Hydrochloride   Extended-Release Tablets + Glyburide*</content>
                           </td>
                           <td rowspan="2">
                              <content styleCode="bold">Placebo   + Glyburide*</content>
                              <content styleCode="bold">(n   = 144)</content>
                           </td>
                        </tr>
                        <tr>
                           <td>
                              <content styleCode="bold">1,500 mg Once</content>
                              <content styleCode="bold">Daily   </content>
                              <content styleCode="bold">(n = 144)</content>
                           </td>
                           <td>
                              <content styleCode="bold">1,000 mg</content>
                              <content styleCode="bold">Twice Daily (n = 141)</content>
                           </td>
                           <td>
                              <content styleCode="bold">2,000 mg Once</content>
                              <content styleCode="bold">Daily   </content>
                              <content styleCode="bold">(n = 146)</content>
                           </td>
                        </tr>
                        <tr>
                           <td align="left">
                              <content styleCode="bold">HbA1c (%), N</content>
                           </td>
                           <td>   136   </td>
                           <td>   136   </td>
                           <td>   144   </td>
                           <td>   141   </td>
                        </tr>
                        <tr>
                           <td align="left">   Baseline   </td>
                           <td>   7.9   </td>
                           <td>   7.8   </td>
                           <td>   7.7   </td>
                           <td>   8.1   </td>
                        </tr>
                        <tr>
                           <td align="left">   Mean Change at   Final Visit   </td>
                           <td>   -0.7   </td>
                           <td>   -0.8   </td>
                           <td>   -0.7   </td>
                           <td>   -0.1   </td>
                        </tr>
                        <tr>
                           <td align="left">   Mean Difference   from   Glyburide Alone   (95% CI)   </td>
                           <td>   -0.8<sup>a</sup> (-1.0, -0.6)   </td>
                           <td>   -0.9<sup>a</sup> (-1.1, -0.7)   </td>
                           <td>   -0.8<sup>a</sup> (-1.0, -0.6)   </td>
                           <td>   N/A   </td>
                        </tr>
                        <tr>
                           <td align="left">
                              <content styleCode="bold">Fasting Plasma Glucose</content>
                              <content styleCode="bold">(mg/dL), N</content>
                           </td>
                           <td>   143   </td>
                           <td>   141   </td>
                           <td>   145   </td>
                           <td>   144   </td>
                        </tr>
                        <tr>
                           <td align="left">   Baseline   </td>
                           <td>   163   </td>
                           <td>   163   </td>
                           <td>   159   </td>
                           <td>   164   </td>
                        </tr>
                        <tr>
                           <td align="left">   Mean Change at   Final Visit   </td>
                           <td>   -14   </td>
                           <td>   -16   </td>
                           <td>   -9   </td>
                           <td>   16   </td>
                        </tr>
                        <tr>
                           <td align="left">   Mean Difference   from   Glyburide Alone   (95% CI)   </td>
                           <td>   -29.2<sup>a</sup> (-39, -20)   </td>
                           <td>   -31.2<sup>a</sup> (-41, -22)   </td>
                           <td>   -24.9<sup>a</sup> (-35, -15)   </td>
                           <td>   N/A   </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>*Glyburide was administered as 10 mg at breakfast and 5 mg at dinner.  </paragraph>
                  <paragraph>
                     <sup>a</sup> p-value for pairwise comparison &lt; 0.001</paragraph>
                  <paragraph>Mean baseline body weight was 89.4 kg, 103.7 kg, 102.9 kg and 95.6 kg in the metformin hydrochloride extended-release tablets 1,500 mg once daily, metformin hydrochloride 1,500 mg in divided doses, metformin hydrochloride extended-release tablets 2,000 mg once daily and metformin HCl tablets 1,500 mg in divided doses arms, respectively. Mean change in body weight from baseline to week 24 was 0.3 kg, 0.1 kg, 0 kg, and 0.7 kg in the metformin hydrochloride extended-release tablets 1,500 mg once daily, metformin hydrochloride extended-release tablets 1,500 mg in divided doses, metformin hydrochloride extended-release tablets 2,000 mg once daily and metformin HCl tablets 1,500 mg in divided doses arms, respectively.</paragraph>
               </text>
               <effectiveTime value="20191010"/>
            </section>
         </component>
         <component>
            <section ID="HOW_SUPPLIED">
               <id root="7fb11855-7684-86cc-cbe9-dad1a8784a93"/>
               <code code="34069-5" displayName="HOW SUPPLIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph>Metformin hydrochloride extended-release tablets, USP are supplied as:</paragraph>
                  <paragraph/>
                  <paragraph>500 mg - white to off-white, oval, beveled edge, biconvex film-coated tablet. Engraved “M5” on one side, plain on the other side.   </paragraph>
                  <paragraph> Bottles of 100 with child-resistant closure, NDC 60505-4700-1 </paragraph>
                  <paragraph/>
                  <paragraph> 1,000 mg - white to off-white, oval, beveled edge, biconvex film-coated tablets. Engraved “M” on one side, “A” on the other side.   </paragraph>
                  <paragraph> Bottles of 90 with child-resistant closure, NDC 60505-4701-9 </paragraph>
                  <paragraph/>
                  <paragraph>Store at 20°C to 25°C (68°F to 77°F); excursions permitted from 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature].</paragraph>
               </text>
               <effectiveTime value="20220228"/>
            </section>
         </component>
         <component>
            <section ID="INFORMATION_FOR_PATIENTS">
               <id root="43969f5f-5360-8493-486f-adbc0e0c7892"/>
               <code code="34076-0" displayName="INFORMATION FOR PATIENTS SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>Advise the patient to read the FDA-approved patient labeling (Patient Information).   </paragraph>
                  <paragraph>
                     <content styleCode="italics">Lactic Acidosis:</content>
                  </paragraph>
                  <paragraph>Explain the risks of lactic acidosis, its symptoms, and conditions that predispose to its development. Advise patients to discontinue metformin hydrochloride extended-release tablets immediately and to promptly notify their healthcare provider if unexplained hyperventilation, myalgias, malaise, unusual somnolence or other nonspecific symptoms occur. Counsel patients against excessive alcohol intake and inform patients about importance of regular testing of renal function while receiving metformin hydrochloride extended-release tablets. Instruct patients to inform their doctor that they are taking metformin hydrochloride extended-release tablets prior to any surgical or radiological procedure, as temporary discontinuation may be required <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#_ae6d682f-d855-4b68-f67a-cfba27a7d629">5.1</linkHtml>)].</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="italics">Hypoglycemia </content>
                  </paragraph>
                  <paragraph>Inform patients that hypoglycemia may occur when metformin hydrochloride extended-release tablets are coadministered with oral sulfonylureas and insulin. Explain to patients receiving concomitant therapy the risks of hypoglycemia, its symptoms and treatment, and conditions that predispose to its development <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#_0cbe5ec8-7ea8-1dd6-b9c4-a308ea0009d1">5.3</linkHtml>)].</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="italics">Vitamin B<sub>12</sub> Deficiency: </content>
                  </paragraph>
                  <paragraph> Inform patients about importance of regular hematological parameters while receiving metformin hydrochloride extended-release tablets <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#_c866af6b-c1c8-f372-93d1-c4da5a4bae52">5.2</linkHtml>)].</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="italics"/>
                     <content styleCode="italics">Females of Reproductive Age: </content>
                  </paragraph>
                  <paragraph>Inform females that treatment with metformin hydrochloride extended-release tablets may result in ovulation in some premenopausal anovulatory women which may lead to unintended pregnancy <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#NURSING_MOTHERS">8.3</linkHtml>)].</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="italics">Administration Information: </content>
                  </paragraph>
                  <paragraph> Inform patients that metformin hydrochloride extended-release tablets must be swallowed whole and not crushed, cut, or chewed, and that the inactive ingredients may occasionally be eliminated in the feces as a soft mass that may resemble the original tablet.</paragraph>
                  <paragraph>
                     <content styleCode="bold"/>Dispense with Patient Information Leaflet available at <content styleCode="underline">www1.apotex.com/products/us</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">APOTEX INC.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Metformin Hydrochloride Extended-Release Tablets, USP</content>
                     <content styleCode="bold"/>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="bold">500 mg, </content>1000 mg</content>
                  </paragraph>
                  <table>
                     <tbody>
                        <tr>
                           <td>
                              <content styleCode="bold">Manufactured by</content>
                              <content styleCode="bold"/>
                              <br/> Apotex Inc.<br/> Toronto, Ontario<content styleCode="bold"/>
                              <br/> Canada M9L 1T9<content styleCode="bold"/>
                           </td>
                           <td>
                              <content styleCode="bold">Manufactured for</content>
                              <content styleCode="bold"/>
                              <br/> Apotex Corp. <br/> Weston, Florida, <br/> USA 33326<content styleCode="bold"/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>Revised: February 2022</paragraph>
                  <paragraph> Rev. 7</paragraph>
               </text>
               <effectiveTime value="20220228"/>
            </section>
         </component>
         <component>
            <section ID="_dbaeec14-5fb3-bb56-0a4b-7d7c057ab7f3">
               <id root="5597a556-fa00-6669-b347-7b4f2239de63"/>
               <code code="42230-3" displayName="SPL PATIENT PACKAGE INSERT SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>PATIENT INFORMATION</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Metformin Hydrochloride Extended-Release Tablets, USP </content>
                     <content styleCode="bold">
                        <br/>(met for' min hye'' droe klor' ide)</content>
                     <content styleCode="bold"/>
                  </paragraph>
                  <paragraph> Patient Information Leaflet available at <content styleCode="underline">www1.apotex.com/products/us</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">What is the most important information I should know about metformin hydrochloride extended-release tablets? </content>
                     <content styleCode="bold"/>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Metformin hydrochloride extended-release tablets can cause serious side effects, including:</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Lactic acidosis. Metformin hydrochloride, the medicine in metformin hydrochloride extended-release tablets, can cause a rare, but serious side effect called lactic acidosis (a buildup of lactic acid in the blood) that can cause death. Lactic acidosis is a medical emergency and must be treated in the hospital.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Stop taking metformin hydrochloride extended-release tablets and call your doctor right away if you get any of the following symptoms of lactic acidosis:</content>
                  </paragraph>
                  <table frame="box" rules="all">
                     <tbody>
                        <tr>
                           <td>
                              <list>
                                 <item>feel very weak and tired</item>
                                 <item>have unusual (not normal) muscle pain</item>
                                 <item>have trouble breathing</item>
                                 <item>have unexplained stomach or intestinal problems with nausea and vomiting, or diarrhea </item>
                              </list>
                           </td>
                           <td>
                              <list>
                                 <item>have unusual sleepiness or sleep longer than usual</item>
                                 <item>feel cold, especially in your arms and legs</item>
                                 <item>feel dizzy or lightheaded</item>
                                 <item>have a slow or irregular heartbeat </item>
                              </list>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="bold">You have a higher chance of getting lactic acidosis if you:</content>
                  </paragraph>
                  <paragraph/>
                  <list>
                     <item>have severe kidney problems. See <content styleCode="bold">“Do not take metformin hydrochloride extended-release tablets if you”</content>
                     </item>
                     <item>have liver problems.</item>
                     <item>drink a lot of alcohol (very often or short-term binge drinking).</item>
                     <item>get dehydrated (lose a large amount of body fluids). This can happen if you are sick with a fever, vomiting, or diarrhea. Dehydration can also happen when you sweat a lot with activity or exercise and do not drink enough fluids.</item>
                     <item>have certain x-ray tests with injectable dyes or contrast agents.</item>
                     <item>have surgery or other procedure for which you need to restrict the amount of food and liquid you eat and drink.</item>
                     <item>have congestive heart failure.</item>
                     <item>have a heart attack, severe infection, or stroke.</item>
                     <item>are 65 years of age or older.</item>
                  </list>
                  <paragraph>Tell your doctor if you have any of the problems in the list above. </paragraph>
                  <paragraph> Tell your doctor that you are taking metformin hydrochloride extended-release tablets before you have surgery or x-ray tests. Your doctor may need to stop metformin hydrochloride extended-release tablets for a while if you have surgery or certain x-ray tests.</paragraph>
                  <paragraph>Metformin hydrochloride extended-release tablets can have other serious side effects. See <content styleCode="bold">“What are the possible side effects of metformin hydrochloride extended-release tablets?”.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">What are metformin hydrochloride</content> <content styleCode="bold">extended-release tablets?</content>
                  </paragraph>
                  <paragraph/>
                  <list>
                     <item>Metformin hydrochloride extended-release tablets are a prescription medicine that contains metformin hydrochloride. Metformin hydrochloride extended-release tablets are used with diet and exercise to help control high blood sugar (hyperglycemia) in adults with type 2 diabetes.</item>
                  </list>
                  <paragraph>It is not known if metformin hydrochloride extended-release tablets are safe and effective in children.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Do not take metformin hydrochloride</content> <content styleCode="bold">extended-release tablets if you:</content>
                  </paragraph>
                  <list>
                     <item>have severe kidney problems.</item>
                     <item>are allergic to metformin hydrochloride or any of the ingredients in metformin hydrochloride extended-release tablets. See the end of this Patient Information leaflet for a complete list of ingredients in metformin hydrochloride extended-release tablets.</item>
                     <item>have a condition called metabolic acidosis, including diabetic ketoacidosis (high levels of certain acids called “ketones” in your blood or urine).</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Before taking metformin hydrochloride extended-release tablets tell your doctor about all of your medical conditions, including if you:</content>
                  </paragraph>
                  <list>
                     <item>have a history or risk for diabetic ketoacidosis. See <content styleCode="bold">“Do not take metformin hydrochloride</content> <content styleCode="bold">extended-release tablets if you:”.</content>
                     </item>
                     <item>have kidney problems.</item>
                     <item>have liver problems.</item>
                     <item>have heart problems, including congestive heart failure.</item>
                     <item>are 65 years of age or older.</item>
                     <item>drink alcohol very often, or drink a lot of alcohol in short-term “binge” drinking.</item>
                     <item>are taking insulin or a sulfonylurea medicine.</item>
                     <item>are pregnant or plan to become pregnant. It is not known if metformin hydrochloride extended-release tablets can harm your unborn baby. If you are pregnant, talk with your doctor about the best way to control your blood sugar while you are pregnant.</item>
                     <item>are a woman who has not gone through menopause (premenopausal) who does not have periods regularly or at all. Metformin hydrochloride extended-release tablets can cause the release of an egg from an ovary in a woman (ovulation). This can increase your chance of getting pregnant.</item>
                     <item>are breastfeeding or plan to breastfeed. Metformin hydrochloride can pass into your breast milk. Talk with your doctor about the best way to feed your baby while you take metformin hydrochloride extended-release tablets.</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Tell your doctor about all the medicines you take, </content>including prescription and over-the-counter medicines, vitamins and herbal supplements. Know the medicines you take. Keep a list of them to show your doctor and pharmacist. Talk to your doctor before you start any new medicine.   </paragraph>
                  <paragraph> Metformin hydrochloride extended-release tablets may affect the way other medicines work, and other medicines may affect how metformin hydrochloride extended-release tablets work.</paragraph>
                  <paragraph>
                     <content styleCode="bold">How should I take metformin hydrochloride extended-release tablets?</content>
                  </paragraph>
                  <list>
                     <item>Take metformin hydrochloride extended-release tablets exactly as your doctor tells you.</item>
                     <item>Metformin hydrochloride extended-release tablets should be taken 1 time each day with your evening meal to help decrease an upset stomach.</item>
                     <item>Swallow metformin hydrochloride extended-release tablets whole. Do not crush, cut, or chew the tablets.</item>
                     <item>You may sometimes pass a soft mass in your stools (bowel movement) that looks like metformin hydrochloride extended-release tablets. This is normal and will not affect the way metformin hydrochloride extended-release tablets work.</item>
                     <item>When your body is under some type of stress, such as fever, trauma (such as a car accident), infection, or surgery, the amount of diabetes medicine that you need may change. Tell your doctor right away if you have any of these problems.</item>
                     <item>Your doctor should do blood tests to check how well your kidneys are working before and during your treatment with metformin hydrochloride extended-release tablets.</item>
                     <item>Your doctor will check your diabetes with regular blood tests, including your blood sugar levels and your hemoglobin A1C.</item>
                     <item>Low blood sugar (hypoglycemia) can happen more often when metformin hydrochloride extended-release tablets are taken with certain other diabetes medicines. Talk to your doctor about how to prevent, recognize, and manage low blood sugar. See <content styleCode="bold">“What are the possible side effects of metformin hydrochloride extended-release tablets?”.</content>
                     </item>
                     <item>Check your blood sugar as your doctor tells you to.</item>
                     <item>Stay on your prescribed diet and exercise program while taking metformin hydrochloride extended-release tablets.</item>
                     <item>If you miss a dose of metformin hydrochloride extended-release tablets, take your next dose at the normal schedule. Do not take 2 doses of metformin hydrochloride extended-release tablets on the same day.</item>
                     <item>If you take too much metformin hydrochloride extended-release tablets, call your doctor or go to the nearest hospital emergency room right away.</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">What should I avoid while taking metformin hydrochloride extended-release tablets?</content>
                  </paragraph>
                  <paragraph> Do not drink a lot of alcoholic drinks while taking metformin hydrochloride extended-release tablets. This means you should not binge drink for short periods, and you should not drink a lot of alcohol on a regular basis. Alcohol can increase the chance of getting lactic acidosis.</paragraph>
                  <paragraph>
                     <content styleCode="bold">What are the possible side effects of metformin hydrochloride</content> <content styleCode="bold">extended-release tablets? </content>
                     <content styleCode="bold"/>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Metformin hydrochloride extended-release tablets can cause serious side effects, including:</content>
                  </paragraph>
                  <list>
                     <item>See <content styleCode="bold">“What is the most important information I should know about metformin hydrochloride</content> <content styleCode="bold">extended-release tablets?”.</content>
                        <content styleCode="bold"/>
                     </item>
                     <item>
                        <content styleCode="bold">Low vitamin B</content>
                        <content styleCode="bold">
                           <sub>12</sub> (vitamin B<sub>12</sub> deficiency). </content>Using metformin hydrochloride extended-release tablets may cause a decrease in the amount of vitamin B<sub>12</sub> in your blood, especially if you have had low vitamin B<sub>12</sub> levels before. Your doctor may do blood tests to check your vitamin B<sub>12</sub> levels.<content styleCode="bold"/>
                     </item>
                     <item>
                        <content styleCode="bold">Low blood sugar (hypoglycemia). Low blood sugar is a serious, but common, side effect of metformin hydrochloride extended-release tablets. </content>If you take metformin hydrochloride extended-release tablets with another medicine that can cause low blood sugar, such as sulfonylureas or insulin, you have a higher risk of getting low blood sugar. The dose of your sulfonylurea medicine or insulin may need to be lowered while you take metformin hydrochloride extended-release tablets. Signs and symptoms of low blood sugar may include:</item>
                  </list>
                  <table>
                     <tbody>
                        <tr>
                           <td>
                              <list>
                                 <item>headache</item>
                                 <item>drowsiness </item>
                                 <item>weakness</item>
                                 <item>irritability</item>
                              </list>
                           </td>
                           <td>
                              <list>
                                 <item>hunger</item>
                                 <item>fast heartbeat </item>
                                 <item>confusion </item>
                                 <item>shaking or feeling jittery </item>
                              </list>   </td>
                           <td>
                              <list>
                                 <item>dizziness</item>
                                 <item>sweating</item>
                              </list>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="bold">The most common side effects of metformin hydrochloride extended-release tablets include:</content>
                  </paragraph>
                  <list>
                     <item>diarrhea</item>
                     <item>nausea</item>
                  </list>
                  <paragraph>These are not all of the possible side effects of metformin hydrochloride extended-release tablets. </paragraph>
                  <paragraph>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</paragraph>
                  <paragraph>
                     <content styleCode="bold">How should I store metformin hydrochloride extended-release tablets?</content>
                  </paragraph>
                  <list>
                     <item>Store metformin hydrochloride extended-release tablets at room temperature between 68°F to 77°F (20°C to 25°C).</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Keep metformin hydrochloride extended-release tablets and all medicines out of the reach of children.</content>   <content styleCode="bold"/>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">General information about the safe and effective use of metformin hydrochloride extended-release tablets</content>
                  </paragraph>
                  <paragraph> Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use metformin hydrochloride extended-release tablets for a condition for which it was not prescribed. Do not give metformin hydrochloride extended-release tablets to other people, even if they have the same symptoms you have. It may harm them.</paragraph>
                  <paragraph>You can ask your pharmacist or doctor for information about metformin hydrochloride extended-release tablets that is written for health professionals.</paragraph>
                  <paragraph>
                     <content styleCode="bold">What are the ingredients in metformin hydrochloride</content> <content styleCode="bold">extended-release tablets? </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Active Ingredient: </content>metformin hydrochloride</paragraph>
                  <paragraph>
                     <content styleCode="bold">Inactive Ingredient:</content> 500 mg and 1,000 mg tablet: carbomer homopolymer type A, carbomer homopolymer type B, dibasic calcium phosphate, dibutyl sebacate, ethylcellulose, hypromellose and magnesium stearate.</paragraph>
                  <paragraph>For more information, go to www.apotex.com or call at 1-800-706-5575.   </paragraph>
                  <paragraph> This Patient Information has been approved by the U.S. Food and Drug Administration.</paragraph>
                  <paragraph>
                     <content styleCode="bold">APOTEX INC.</content>
                     <content styleCode="bold"/>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Metformin Hydrochloride Extended-Release Tablets, USP</content>
                     <content styleCode="bold"/>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="bold">500 mg, </content>1000 mg</content>
                  </paragraph>
                  <table>
                     <tbody>
                        <tr>
                           <td>
                              <content styleCode="bold">Manufactured by</content>
                              <br/> Apotex Inc.<br/> Toronto, Ontario<content styleCode="bold"/>
                              <br/> Canada M9L 1T9<content styleCode="bold"/>
                           </td>
                           <td>
                              <content styleCode="bold">Manufactured for</content>
                              <br/> Apotex Corp. <br/> Weston, Florida, <br/> USA 33326<content styleCode="bold"/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="bold"/>Revised: February 2022</paragraph>
                  <paragraph>Rev. 7</paragraph>
                  <paragraph>
                     <content styleCode="bold"/>
                  </paragraph>
                  <paragraph/>
                  <paragraph/>
                  <paragraph/>
                  <paragraph/>
                  <paragraph/>
                  <paragraph/>
                  <paragraph/>
               </text>
               <effectiveTime value="20220228"/>
            </section>
         </component>
         <component>
            <section ID="_f7e5aa7d-9c7b-a77e-80ed-24dcb57fadb6">
               <id root="420549c3-4aa5-4883-84b9-91247b9a4821"/>
               <code code="51945-4" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL" codeSystem="2.16.840.1.113883.6.1"/>
               <title>PRINCIPAL DISPLAY PANEL - BOTTLE LABEL 1000 mg </title>
               <text>
                  <paragraph>Representative sample of labeling (see <linkHtml href="#HOW_SUPPLIED">HOW SUPPLIED</linkHtml> section of complete listing):</paragraph>
                  <paragraph>
                     <content styleCode="bold">APOTEX CORP.</content>
                  </paragraph>
                  <paragraph>NDC 60505-4701-9</paragraph>
                  <paragraph>Metformin Hydrochloride Extended-Release Tablets, USP </paragraph>
                  <paragraph> 1000 mg 90s</paragraph>
                  <paragraph>Rx </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM281178756381"/>
                  </paragraph>
               </text>
               <effectiveTime value="20190320"/>
            </section>
         </component>
         <component>
            <section ID="_de47c7e5-a6af-940f-24ad-f0c45943b595">
               <id root="70bcaa58-7114-b04d-6e42-700f718a2179"/>
               <code code="51945-4" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL" codeSystem="2.16.840.1.113883.6.1"/>
               <title>PRINCIPAL DISPLAY PANEL - BOTTLE LABEL 500 mg</title>
               <text>
                  <paragraph>Representative sample of labeling (see <linkHtml href="#HOW_SUPPLIED">HOW SUPPLIED</linkHtml> section of complete listing):</paragraph>
                  <paragraph>
                     <content styleCode="bold">APOTEX CORP.</content>
                  </paragraph>
                  <paragraph>NDC 60505-4700-1</paragraph>
                  <paragraph>Metformin Hydrochloride Extended-Release Tablets, USP </paragraph>
                  <paragraph> 500 mg 100s</paragraph>
                  <paragraph>Rx </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM309767141769"/>
                  </paragraph>
               </text>
               <effectiveTime value="20190710"/>
            </section>
         </component>
      </structuredBody>
   </component>
</document>